Enzon Pharmaceuticals, Inc. (ENZN) Widens Q3 Loss on Lighter Sales
Tweet
Share
E-mailGet Alerts ENZN Hot Sheet
Join SI Premium – FREE
Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) reported Q3 EPS of ($0.19), versus ($0.14) reported last year. Revenue for the quarter came in at $10.44 million, versus $13.23 million reported last year.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SYNNEX Corp. (SNX) Tops Q3 EPS by $1.04, Beats on Revenue; Offers Q4 Guidance
- Espey Manufacturing (ESP) Tops Q4 EPS by 24c
- KB Home (KBH) Tops Q3 EPS by 16c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
